|Bid||80.00 x 0|
|Ask||81.00 x 0|
|Day's Range||80.00 - 81.40|
|52 Week Range||41.00 - 99.80|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 29, 2017|
|1y Target Est||148.90|
Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN) Approximately 160 patients.
Key Highlights: Talicia® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020 Acquisition.
Key Highlights: U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including.
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V. (SIX:COPN) (“Cosmo”). The strategic collaboration includes an exclusive license agreement for the U.S. rights to Aemcolo® (rifamycin) and a simultaneous private investment by Cosmo of $36.3 million in RedHill at $7.00 per American Depositary Share (ADS), representing approximately 13.5% over the closing price on October 17, 2019, with a 180-day transfer restriction.